Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Aura Biosciences, Inc. reported that director and officer Natalie C. Holles received significant equity awards in the form of restricted stock units, performance RSUs and stock options. She was granted 553,844 RSUs as Inducement Awards, each representing one share of common stock, vesting in four equal annual installments beginning on April 15, 2027, subject to continued service.
She also received 600,118 performance RSUs as Inducement Awards that require both time-based vesting and achievement of a performance condition. These PRSUs vest in four equal annual installments commencing on April 15, 2027 and expire on the earlier of the sixth anniversary of the grant date or the date her service with the company ends, with any unvested awards then forfeited.
In addition, Holles was granted a stock option covering 2,169,103 shares of common stock at an exercise price of $7.3900 per share, expiring on May 19, 2036. Twenty-five percent of the option vests on April 30, 2027, with the remainder vesting pro rata in 36 monthly installments, subject to continued service. Following these grants, she directly owns 1,153,962 shares of common stock.
Aura Biosciences, Inc. ownership disclosure: a group of TCG Crossover entities and Chen Yu report shared beneficial ownership positions in Common Stock following an underwritten offering that closed on May 5, 2026.
The filing shows Chen Yu (through affiliated funds and GPs) holds 9,533,333 shares (listed as 9.9%) on the cover page and each TCG fund/entity is shown with ~4,766,666–4,766,667 shares (~5.0% each). The disclosure excludes aggregate 3,800,000 shares subject to Pre-Funded Warrants not exercisable within 60 days because of a 9.99% Beneficial Ownership Limitation. The filing cites a base share reference of 103,178,777 shares outstanding as of May 5, 2026, and an adjusted denominator of 96,255,907 derived by subtracting 6,922,870 shares assuming a repurchase described in the prospectus.
Aura Biosciences, Inc. reported a large insider sale of its common stock connected to Matrix Capital entities. Matrix Capital Management Master Fund, LP sold 6,922,870 shares of common stock at $5.64 per share in an open-market transaction on May 7, 2026.
The shares are held by Matrix Capital Management Master Fund, LP, with Matrix Capital Management Company, LP as investment adviser and David E. Goel as managing general partner. The reporting persons indicate that the reported position is now zero shares and expressly disclaim beneficial ownership beyond any pecuniary interest.
Aura Biosciences reported a larger quarterly loss as it ramps up late-stage development of its lead cancer drug bel-sar. For the three months ended March 31, 2026, the company recorded a net loss of $33.7 million, compared with $27.5 million a year earlier, driven mainly by higher research and development and general and administrative expenses.
Cash, cash equivalents and marketable securities totaled $114.7 million at March 31, 2026. After quarter-end, Aura completed a 2026 follow-on equity offering, raising net proceeds of about $280.8 million and using roughly $39.0 million to repurchase 6,922,870 shares from a major stockholder, steps that management believes extend its funding runway into the second half of 2028 and alleviate prior going concern uncertainty.
Aura Biosciences, Inc. disclosed that Matrix Capital Management and David E. Goel have filed an Amendment No. 4 to their Schedule 13D, reporting that they no longer beneficially own any shares of Aura’s common stock and now hold 0% of the class.
The change follows a share repurchase in which the Matrix Fund agreed on April 30, 2026 to sell, and Aura agreed to repurchase, 6,922,870 shares of common stock at $5.64 per share, contingent on a separate equity offering and other conditions. The repurchase closed on May 7, 2026, and this amendment is described as the final, “exit filing” for the reporting persons.
Aura Biosciences reported a net loss of $33.7 million for the quarter ended March 31, 2026, wider than $27.5 million a year earlier, as it increased investment in late- and early-stage trials. Research and development expenses rose to $28.0 million, and general and administrative costs grew to $6.9 million.
The company ended the quarter with $114.7 million in cash, cash equivalents and marketable securities, then completed an oversubscribed $299 million equity financing on May 5, 2026, generating $280.8 million in net proceeds and using about $39.0 million to repurchase shares from Matrix Capital. Aura now expects its cash resources to fund operations into the second half of 2028.
Clinically, the Phase 3 CoMpass trial of bel-sar in early choroidal melanoma is progressing toward enrollment completion by mid‑2026 with topline data anticipated in the second half of 2027, while additional studies in metastases to the choroid, ocular surface cancers and non‑muscle invasive bladder cancer advance. Natalie Holles has been appointed Chief Executive Officer and President, succeeding founder Elisabet de los Pinos.
Aura Biosciences, Inc. filed an initial insider ownership report for Natalie C. Holles, who is identified as both a director and an officer. The Form 3 data show no reported share purchases, sales, gifts, or option exercises, with all transaction counts and net share changes at zero.
Aura Biosciences, Inc. completed an underwritten public offering of 39,591,000 common shares and pre-funded warrants to purchase up to 3,800,000 shares, all sold by the company. The underwriters also exercised in full their option to buy an additional 6,508,650 shares.
The shares were priced at $6.00 each, while each pre-funded warrant was priced at $5.99999 with a $0.00001 exercise price and is exercisable immediately, subject to ownership caps between 4.99% and 19.99%. Aura Biosciences received approximately $280.8 million in net proceeds.
The company plans to use about $241.8 million to advance clinical programs, including early choroidal melanoma and registration-enabling activities for bel-sar, and for general corporate purposes. It intends to use approximately $39.0 million to repurchase 6,922,870 shares from Matrix Capital Management Master Fund, LP at $5.64 per share. Aura Biosciences believes these resources will fund operations and capital needs into the second half of 2028.
Aura Biosciences is offering 39,591,000 shares of common stock and pre-funded warrants to purchase up to 3,800,000 additional shares. The offering is being sold at $6.00 per share (pre-funded warrant price $5.99999) with expected net proceeds of approximately $244.1 million after underwriting discounts and commissions, excluding any proceeds from warrant exercises.
The company intends to use about $39.0 million of net proceeds to repurchase 6,922,870 shares from Matrix Capital Management Master Fund, LP at $5.64 per share, and approximately $205.1 million to advance clinical programs and registration-enabling activities for bel-sar. Preliminary cash, cash equivalents and marketable securities were approximately $114.7 million as of March 31, 2026. The offering includes an underwriter option for 6,508,650 additional shares and the company reiterated Phase 3 CoMpass enrollment guidance (near-completion by mid-2026) with topline data expected in H2 2027.
Aura Biosciences is offering 39,591,000 shares of common stock and pre-funded warrants to purchase up to 3,800,000 additional shares. The offering is being sold at $6.00 per share (pre-funded warrant price $5.99999) with expected net proceeds of approximately $244.1 million after underwriting discounts and commissions, excluding any proceeds from warrant exercises.
The company intends to use about $39.0 million of net proceeds to repurchase 6,922,870 shares from Matrix Capital Management Master Fund, LP at $5.64 per share, and approximately $205.1 million to advance clinical programs and registration-enabling activities for bel-sar. Preliminary cash, cash equivalents and marketable securities were approximately $114.7 million as of March 31, 2026. The offering includes an underwriter option for 6,508,650 additional shares and the company reiterated Phase 3 CoMpass enrollment guidance (near-completion by mid-2026) with topline data expected in H2 2027.
Aura Biosciences is offering 39,591,000 shares of common stock and pre-funded warrants to purchase up to 3,800,000 additional shares. The offering is being sold at $6.00 per share (pre-funded warrant price $5.99999) with expected net proceeds of approximately $244.1 million after underwriting discounts and commissions, excluding any proceeds from warrant exercises.
The company intends to use about $39.0 million of net proceeds to repurchase 6,922,870 shares from Matrix Capital Management Master Fund, LP at $5.64 per share, and approximately $205.1 million to advance clinical programs and registration-enabling activities for bel-sar. Preliminary cash, cash equivalents and marketable securities were approximately $114.7 million as of March 31, 2026. The offering includes an underwriter option for 6,508,650 additional shares and the company reiterated Phase 3 CoMpass enrollment guidance (near-completion by mid-2026) with topline data expected in H2 2027.
Aura Biosciences, Inc. entered into a Repurchase Agreement with Matrix Capital Management Master Fund to buy back up to 6,922,870 shares of its common stock in a privately negotiated transaction. The repurchase price per share will match the price at which underwriters purchase shares in the company’s separately announced underwritten equity offering, which was set at $5.64 per share.
The company plans to fund the repurchase using a portion of net proceeds from the equity offering that exceed $200 million, after underwriting discounts and commissions. Matrix held approximately 10.8% of Aura’s outstanding common stock as of April 15, 2026. The stock repurchase is subject to the successful closing of the equity offering and other conditions and may not occur. Aura also disclosed preliminary cash, cash equivalents and marketable securities of about $114.7 million as of March 31, 2026, which are unaudited and subject to final accounting.
Aura Biosciences, Inc. entered into a Repurchase Agreement with Matrix Capital Management Master Fund to buy back up to 6,922,870 shares of its common stock in a privately negotiated transaction. The repurchase price per share will match the price at which underwriters purchase shares in the company’s separately announced underwritten equity offering, which was set at $5.64 per share.
The company plans to fund the repurchase using a portion of net proceeds from the equity offering that exceed $200 million, after underwriting discounts and commissions. Matrix held approximately 10.8% of Aura’s outstanding common stock as of April 15, 2026. The stock repurchase is subject to the successful closing of the equity offering and other conditions and may not occur. Aura also disclosed preliminary cash, cash equivalents and marketable securities of about $114.7 million as of March 31, 2026, which are unaudited and subject to final accounting.
Aura Biosciences, Inc. entered into a Repurchase Agreement with Matrix Capital Management Master Fund to buy back up to 6,922,870 shares of its common stock in a privately negotiated transaction. The repurchase price per share will match the price at which underwriters purchase shares in the company’s separately announced underwritten equity offering, which was set at $5.64 per share.
The company plans to fund the repurchase using a portion of net proceeds from the equity offering that exceed $200 million, after underwriting discounts and commissions. Matrix held approximately 10.8% of Aura’s outstanding common stock as of April 15, 2026. The stock repurchase is subject to the successful closing of the equity offering and other conditions and may not occur. Aura also disclosed preliminary cash, cash equivalents and marketable securities of about $114.7 million as of March 31, 2026, which are unaudited and subject to final accounting.